Twice-daily radiation linked to better quality of life in lung cancer trial

Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population.